FDA advisers recommend against Delcath's cancer therapy

(Reuters) - A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news